SEARCHFounded in 2004, CardioDx®, Inc., is a cardiovascular genomic diagnostics company located in Palo Alto, CA. As a pioneer in the field of cardiovascular genomic diagnostics, the company is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia, and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies.
At CardioDx, we fuse expertise in genomics, biostatistics, and cardiology to develop objective, reproducible tests that provide clinicians with information to enhance patient care. In 2010, the company was honored as a winner of the Wall Street Journal’s prestigious Technology Innovation Awards and Corus® CAD was named one of Time Magazine’s Top Ten Medical Breakthroughs. CardioDx is a privately held company funded by Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Company, GE Capital, Longitude Capital, JP Morgan Venture Capital, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM.
Our guiding principles
- We are committed to improving the quality of care for patients.
- We continually seek input from healthcare providers on the development of our products and services.
- We develop our products by conducting rigorous clinical studies, employing innovative technologies, and validating results with independent patient populations.
- We deliver clinically validated and reliable products while providing unparalleled customer service.